(‘AfriAg’ or the ‘Company’)
Apollon, with its new State-of-the-Art Licensed Processing Facility, moving forward to Process and Manufacture its first
-- Three harvests of medical cannabis plants for research have now been successfully completed in Negril,
Jamaica, as permitted per Apollon’s permits from the Jamaican Ministry of Science & Technology. These first cultivations also allow for the establishment of mother plants and clone stock for the increased benefit of future harvests. -- Jamaican Cannabis Licensing Authority(“CLA”) Licenses for Processing and Retail with harvest produced by third party producers (Therapeutic) have been approved and issued. The CLA has also issued a conditional Tier 1 Cultivation License to Apollon for its roof top greenhouse. -- Apollon’s new State-of-the-Art Processing Facility in Negril, Jamaicais taking steps to initiate its 1st production run in order to manufacture Apollon’s retail medical cannabis pharmaceuticals, with the medical cannabis flower procured for retail purposes, being sourced by Apollon from licenced third party growers in Jamiaca as set out in CLA approved tripartied agreements. -- Apollon’s Retail (Therapeutic) Dispensary in Negril, Jamaicais now nearing completion and is expected to begin generating revenue by 1 July 2019. -- Doc’s Place Wellness Resort, which leases space exclusively to Apollon for it to operate a medical cannabis pharmaceutical dispensary and treatment centre, is currently in the final stages of a major refurbishment and upgrade and is on schedule to open and begin generating revenue by the end of July 2019. -- Apollon has received it’s CLA Conditional Approval for Cultivation.Apollon is implementing CLA required changes to its properties in order to obtain approval so that it can begin cultivating retail crop, by third party producers, as set out in the CLA Tier 3 Cultivation Licence it has been awarded.Apollon expects such approval within the next 3 months.
“Apollon is developing its fully vertically integrated medical cannabis business in
As previously announced,
Apollon is a Federally Licensed vertically integrated medical cannabis company operating in
Notice Regarding Forward-Looking Statements
This announcement includes "forward-looking statements" involving the Company, the other entities referenced in this announcement, and the respective subsidiaries, affiliates and associates of the Company and such other entities (collective, the “Involved Entities”), which include all statements other than statements of historical facts, including, without limitation, those regarding the financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Involved Entities that could cause the actual results, performance or achievements of the Involved Entities to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the present and future business strategies of the Involved Entities and the environment in which the Involved Entities will operate in the future. These forward-looking statements speak only as of the date of this announcement. The Company, on behalf of itself and each of the Involved Entities, expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in expectations of any Involved Entities with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.
The directors of the Company accept responsibility for the contents of this announcement.
For further information on AfriAg Global please visit the www.afriagglobal.com or please contact;
Peterhouse Capital Limited +44 (0)20 7469 0930